GSK's Chronic Hepatitis B Drug Meets Primary Endpoints in Late-stage Studies

MT Newswires · 6d ago
02:25 AM EST, 01/07/2026 (MT Newswires) -- GSK (GSK.L) said Wednesday that the two late-stage studies evaluating its drug candidate bepirovirsen for the treatment of chronic hepatitis B met their respective primary endpoints. During the phase 2 B-Well 1 and B-Well 2 trials, the investigational antisense oligonucleotide showed "significantly higher" functional cure rates plus standard of care, compared with standard of care alone. The trials also showed an acceptable safety and tolerability profile for the drug. The British pharmaceutical group plans to submit full results of the trials at an upcoming scientific congress and also commence global regulatory filings with health authorities from the first quarter.